山东华特达因健康股份有限公司 第十一届监事会第三次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 山东华特达因健康股份有限公司第十一届监事会于 2025 年 4 月 7 日以电子邮件形式发出召开第三次会议的通知，并于 2025 年 4 月 17 日在公司会议室召开会议。会议应参加监事 5 名，实际参加监事 5 名。会议由监事会主席沈宝杰先生主持。会议符合有关法律、法规、 规章和《公司章程》的规定。 股票代码：000915 股票简称：华特达因 公告编号：2025-018 经审核，监事会认为董事会编制和审议《公司 2025 年第一季度 报告》的程序符合法律法规及深圳证券交易所规定的要求，报告内容 真实、准确、完整地反映了上市公司的实际情况，不存在任何虚假记 载、误导性陈述或者重大遗漏。 （三）备查文件 经与会监事签字并加盖监事会印章的监事会决议。 特此公告 山东华特达因健康股份有限公司监事会 二、监事会会议审议情况 以 5 票同意 0 票弃权 0 票反对的表决结果，审议通过了《公司 2025 年第一季度报告》并发表如下审核意见 ...

Core Insights - The company reported a revenue of 616 million yuan for the first quarter of 2025, representing a year-on-year growth of 7.78% [1] - The net profit for the same period was 182 million yuan, showing an increase of 8.13% compared to the previous year [1]

证券代码：000915 证券简称：华特达因 公告编号：2025-017 山东华特达因健康股份有限公司 关于拟续聘会计师事务所的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 本次拟续聘会计师事务所符合财政部、国务院国资委、证监会印发的 《国有企业、上市公司选聘会计师事务所管理办法》（财会〔2023〕4 号） 的规定。 （三）诚信记录 致同所近三年因执业行为受到刑事处罚 0 次、行政处罚 2 次、监督管理 措施 15 次、自律监管措施 9 次和纪律处分 0 次。58 名从业人员近三年因 执业行为受到刑事处罚 0 次、行政处罚 11 次、监督管理措施 16 次、自律 监管措施 8 次和纪律处分 1 次。 二、项目信息 （一）人员信息 刘健，2007 年成为注册会计师，1998 年开始从事上市公司审计，2019 年开始在本所执业；近三年签署上市公司审计报告 8 份、签署新三板挂牌 公司审计报告 1 份。复核新三板挂牌公司 1 份。 山东华特达因健康股份有限公司（以下简称"公司"）于 2025 年 4 月 17 日召开第十一届董事会第三次会议，审议通 ...

Group 1: Report Overview - Reported industry: Chemical Pharmaceuticals [2] - Research object: Watertime [17] - Reception time: April 16, 2025 [17] - Listed company reception staff: President Yang Jie, Independent Director Du Ning, Financial Controller Tan Lifu, Board Secretary Fan Liming [17] Group 2: Core Views - The company's cooperation with China Resources Sanjiu on Vitamin D Drops (capsule type) allows for complementary advantages and resource sharing, promoting the popularization of vitamin D supplements [24][44] - In 2024 Q3, the company's performance decline was due to factors such as the slowdown in the pharmaceutical industry, inactive market terminal sales, and intensified pharmacy competition. The company responded by increasing marketing efforts and optimizing strategies [25][45] - The company is promoting the bankruptcy of Watertime Information, the dissolution and liquidation of Watertime Zhixin, and addressing the asset occupation issue of Yinan Watertime Wolong School [26] - The company aims to form multi - category flagship products, optimize channel layout, and build an honest, capable, efficient, and pragmatic corporate culture [26] - The company will adhere to its core marketing strategy, accelerate the layout of OTC and new retail channels, and expand sales through multiple measures to ensure stable performance growth [28][40] Group 3: Q&A Summaries Business and Strategy - The company's mission is to make thousands of Chinese children healthy and strong and become a leading enterprise in the field of children's health care and treatment. It focuses on the pharmaceutical main business, implements category extension and brand extension strategies, and expands the applicable age of Yikexin [34][41] - The company will actively manage its market value through measures such as standardized and transparent information disclosure, strengthening communication with investors, and implementing high - proportion dividends [34][35][42] - In 2025, the company will continue to improve the key technology platform for children's drugs, aiming for breakthroughs in children's respiratory and mental medications [35] Product - related - Yikexin has a market share of over 60%. The company will promote the "AD co - supplementation, 0 - 18 years old, one capsule per day" concept through various channels [34][37] - The company's product line is rich. In addition to Yikexin, products like Dain Tie, Dain Gai, and Xiao'er Ibuprofen Suppository have a broad market space and stable revenue growth [29] - The company's DHA products are designed for 0 - 12 - year - old children to promote eye and brain development, with different formulations to cover a wide range of customers [40] Market and Competition - The company will adhere to its core marketing strategy, strengthen brand promotion, and accelerate the layout of OTC and new retail channels to deal with the impact of competitors' centralized procurement [29][49] - The company's products are mainly sold through dealers, and it has established teams for hospitals, business, OTC, and new retail. The 2024 R & D investment was 97.1389 million yuan, accounting for 4.55% of revenue [47][48] Finance and Dividends - The company will maintain high - proportion dividends in the absence of major business investments and capital requirements, sharing development benefits with shareholders [38][39][47] Industry Outlook - The Chinese pharmaceutical industry is in a period of dual benefits from innovation and policy support, showing an expanding scale and rapid structural optimization. The children's pharmaceutical industry is moving towards precision and safety improvement [36]

Group 1: Company Performance and Financials - The company has maintained a high dividend payout, with the dividend amount for 2024 reaching 119% of the net profit attributable to the parent company [12] - In 2024, the company reported a significant decline in performance, with revenue and profit showing negative growth for the first time since 2019 [10][12] - R&D investment for 2024 was approximately 97.14 million, accounting for 4.55% of revenue [12] Group 2: Market Strategy and Product Development - The company focuses on children's health products, with a mission to become a leader in pediatric healthcare [10] - The market strategy emphasizes "expert authority recommendation, convenient purchasing channels, and professional category education" [11][12] - The company plans to expand the age range for its flagship product, Yikexin, from 0-6 years to 0-18 years, in line with new clinical guidelines [5][10] Group 3: Challenges and Responses - The decline in performance is attributed to a slowdown in the pharmaceutical industry, reduced market activity, and intensified competition among pharmacies [11][12] - The company is actively responding to market changes by increasing marketing efforts and enhancing online channel development [11][12] - The company aims to maintain stable growth by optimizing product structure and increasing R&D investment to introduce more competitive products [12] Group 4: Collaboration and Partnerships - The company collaborates with China Resources Sanjiu as the exclusive agent for its vitamin D products, enhancing market promotion and distribution [11] - Strategic partnerships with major distributors and e-commerce platforms are being strengthened to boost sales and market presence [12] Group 5: Future Outlook - The company is optimistic about the future of the pediatric pharmaceutical market, driven by increasing healthcare demands and supportive government policies [5][10] - Plans for 2025 include focusing on innovation in pediatric medications and expanding the product line to include more health supplements [10][12]

Summary of Conference Call Notes Industry Overview - The conference call focused on the consumer sector, particularly in the areas of healthcare, food and beverage, and retail, following the recent government policies aimed at stimulating consumption after the Two Sessions [1][2]. Key Points and Arguments Consumer Sector Insights - The consumer sector is experiencing a notable recovery, with significant growth observed in healthcare, beauty, and food and beverage sectors post-policy implementation [1]. - The overall strategy for the consumer sector is categorized into three directions: Strong, Change, and New [2][3]. Strong Segments - **Consumer Export**: Key players include Xiaogoods City, Miniso, and Anker Innovations, leveraging China's strong manufacturing supply chain for global branding [3][4]. - **Gold and Jewelry**: The sector is expected to benefit from rising gold prices, with companies like Lao Fengxiang and Chow Tai Fook identified as strong performers. The anticipated recovery in demand is expected to materialize by Q2 2025 [6][8]. Change Segments - Companies undergoing significant transformations, such as Shanghai Jahwa and Xiyu Tourism, are highlighted as potential investment opportunities [10][14]. - The beauty sector is also seen as having a significant opportunity for growth, particularly with the decline in advertising costs on platforms like Douyin [9][10]. New Consumption Trends - New consumption habits are emerging, with brands like Lao Pu Gold and Mi Xue Group being recognized for their innovative approaches and market positioning [11][12][13]. - The tea beverage market is highlighted, with Mi Xue Group being a standout performer due to its strong brand and profitability [13]. Healthcare Sector Insights - The healthcare segment, particularly in ophthalmology, is showing strong recovery, with companies like Purui Eye Hospital and Aier Eye Hospital expected to see revenue growth of 15-20% in Q1 [32][33][34]. - The overall trend in consumer healthcare is positive, with a notable increase in patient flow and service demand [33][36]. OTC and Pharmacy Recommendations - The OTC market, particularly in pediatric medicine, is expected to recover, with companies like Jianmin Group and Huate Dain being recommended for their growth potential [38][41][42]. - The pharmacy sector is also showing signs of recovery, with leading companies achieving positive growth despite previous challenges [38][39]. Additional Important Insights - The overall sentiment is optimistic regarding the consumer sector's recovery, with expectations of policy support and market improvements in the coming quarters [22][23]. - The conference emphasized the importance of identifying companies that have already shown signs of recovery and are positioned for growth as the market stabilizes [16][21][24]. Conclusion - The conference call provided a comprehensive overview of the consumer sector's current state and future potential, highlighting key companies and trends that investors should monitor for opportunities in the coming year [43].

Core Viewpoint - The article highlights the recent movements of social security funds in the A-share market, indicating a growing presence in various companies as they disclose their 2024 annual reports [1]. Group 1: Social Security Fund Holdings - The social security fund entered the top ten shareholders of 52 new stocks in the fourth quarter of 2024 [1]. - Huazhong Pharmaceutical had the highest number of new holdings by the social security fund, with three new positions [1]. - Other companies with two new holdings include Chengdu Investment Holdings, Huate Dain, China Jushi, Chifeng Gold, and Zhongfu Information [1]. Group 2: Company-Specific Financials - **Huazhong Pharmaceutical**: - New holding value reached 384 million yuan - 2024 revenue was 11.212 billion yuan, down 0.87% year-on-year - Net profit was 1.628 billion yuan, down 2.55% year-on-year [2]. - **China Jushi**: - New holding value reached 585 million yuan - 2024 revenue was 15.856 billion yuan, up 6.59% year-on-year - Net profit was 2.445 billion yuan, down 19.70% year-on-year [3]. - **Chifeng Gold**: - New holding value reached 443 million yuan - 2024 revenue was 9.026 billion yuan, up 24.99% year-on-year - Net profit was 1.764 billion yuan, up 119.46% year-on-year [4]. - **Chengdu Investment Holdings**: - New holding value reached 230 million yuan [5]. - **Huate Dain**: - New holding value reached 276 million yuan [5]. - **Zhongfu Information**: - New holding value reached 146 million yuan [5].

↓ 点击"阅读原文" 快速开通天天基金交易账户， 当天开户当天可买基金！ 分享、点赞、在看 顺手三连越来越有钱 社保基金连续持仓超2年的20只个股中，从去年四季度末社保基金持股量来看，招商蛇口、南山铝业、 中国巨石等持股数量居前，社保基金分别持有1.51亿股、1.50亿股、1.02亿股。社保基金持股比例居前 的有华特达因、龙迅股份、神火股份等，持股比例分别为5.98%、4.32%、4.25%。 免责声明 以上观点来自相关机构，不代表天天基金的观点，不对观点的准确性和完整性做任何保证。 收益率数据仅供参考，过往业绩和走势风格不预示未来表现，不构成投资建议。转引的相关 作为风格稳健的长期机构投资者，社保基金长线持有的重仓股引人关注。 据 证 券 时报·数据宝统计，截至3月25日，公布2024年年报公司中，社保基金最新出现在61家公司 前十大流通股东榜。其中，20只社保基金持有期超过两年， 扬农化工 、 中国巨石 等4只获社保基金 连续持仓超5年。 社保基金持有期限最长的个股是 扬农化工 ，自2014年四季度以来已累计持有41个季度，最新全国 社保基金一零六组合，位列公司第三大流通股东，持股量合计为1704.08万 ...

超500亿元！招商银行大手笔分红 Wind数据显示，截至3月26日记者发稿时，共有近300家A股上市公司公布了2024年利润分配方案或股东 分红提议，拟派息金额合计近4000亿元。其中，中国移动以535.78亿元的年度分红金额位列第一，招商银行 以504.4亿元的年度分红金额排第二，中国神华以449.03亿元的年度分红金额位列第三，此外，中国平安年度 分红金额接近300亿元，宁德时代、中国石化、中远海控、交通银行、比亚迪等多家上市公司年度分红金额不 低于100亿元。 从每股派发的现金股利来看，宁德时代拟每股派发4.553元现金股利，目前位居第一；比亚迪拟每股派发 3.974元现金股利，目前位居第二；爱美客拟每股派发3.8元现金股利，目前位居第三；此外，同花顺、中国神 华、中国移动、东鹏饮料、华利集团、招商银行、华特达因、法拉电子等每股拟派发金额不低于2元。 业内人士指出，上市公司重视投资者回报，向投资者传递了积极信号，有助于稳定市场预期。新"国九 条"强化上市公司现金分红监管下，上市公司分红意愿有望进一步提升。 | | | | 本年比上年 | | | --- | --- | --- | --- | --- | ...

关于对会计师事务所2024年度履职情况的评估报告 暨审计委员会履行监督职责情况的报告 一、2024年度会计师事务所基本情况 （一）基本情况 致同会计师事务所（特殊普通合伙）前身是成立于1981年的北 京会计师事务所，2011年12月22日经北京市财政局批准转制为特殊 普通合伙，2012年更名为致同会计师事务所（特殊普通合伙），首 席合伙人李惠琦，注册地址为北京市朝阳区建国门外大街22号赛特 广场5层。 致同所已取得北京市财政局颁发的执业证书（证书序号：NO 0014469），截止2024年末，致同所从业人员超过六千人，其中合伙 人239名，注册会计师1,359名，签署过证券服务业务审计报告的注 册会计师超过400人。 致同所2023年度业务收入27.03亿元，其中审计业务收入22.05 亿元，证券业务收入5.02亿元。2023年度上市公司审计客户257家， 主要行业包括制造业；信息传输、软件和信息技术服务业；批发和 零售业；电力、热力、燃气及水生产供应业；交通运输、仓储和邮 政业，收费总额3.55亿元；2023年年报挂牌公司客户163家，审计收 费3,529.17万元; 其中医药制造业上市公司/新三板挂牌公司 ...